TABLE OF CONTENTS
Volume 9, Issue 3 (September 2006)
Editorial
Report from Durham FREE
J W Moul
Prostate Cancer Prostatic Dis 9: 199; doi:10.1038/sj.pcan.4500908
Research Highlights
Prostate News FREE
Prostate Cancer Prostatic Dis 9: 201-203; doi:10.1038/sj.pcan.4500909
Reviews
Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia FREE
R C Harkaway and M M Issa
Prostate Cancer Prostatic Dis 9: 204-214; advance online publication, June 6, 2006; doi:10.1038/sj.pcan.4500869
Permanent prostate brachytherapy: a century of technical evolution
P L Acher, S L Morris, R J M P Popert, M J A Perry, L Potters and R P Beaney
Prostate Cancer Prostatic Dis 9: 215-220; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500873
The changing pattern of management for hormone-refractory, metastatic prostate cancer
N D James, D Bloomfield and C Luscombe
Prostate Cancer Prostatic Dis 9: 221-229; advance online publication, June 27, 2006; doi:10.1038/sj.pcan.4500880
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Y Liu
Prostate Cancer Prostatic Dis 9: 230-234; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500879
Original Articles
Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA levels between 4 and 10 ng/ml
O Kayg
sz, Ö U
urlu, M Ko
an, G 
nal, B Öztürk and M Çetinkaya
Prostate Cancer Prostatic Dis 9: 235-238; advance online publication, May 23, 2006; doi:10.1038/sj.pcan.4500885
The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml
C Bastide, R Kuefer, M Loeffler, R de Petriconi, J Gschwend and R Hautmann
Prostate Cancer Prostatic Dis 9: 239-244; advance online publication, July 11, 2006; doi:10.1038/sj.pcan.4500892
High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features
C Vargas, A Martínez, R Galalae, J Demanes, A Harsolia, L Schour, N Nuernberg and J Gonzalez
Prostate Cancer Prostatic Dis 9: 245-253; advance online publication, June 20, 2006; doi:10.1038/sj.pcan.4500882
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate
M S Anscher, R Clough, C N Robertson, L R Prosnitz, P Dahm, P Walther, C F Donatucci, D M Albala, P Febbo, D J George, L Sun and J W Moul
Prostate Cancer Prostatic Dis 9: 254-260; advance online publication, August 1, 2006; doi:10.1038/sj.pcan.4500903
More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study
J-S Paick, S C Lee and J H Ku
Prostate Cancer Prostatic Dis 9: 261-265; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500881
Histopathological findings after radiofrequency (RITA) treatment for prostate cancer
C Patriarca, F Bergamaschi, G Gazzano, P Corrada, G Ordesi, L Zanitzer, M Di Pasquale, P Giunta and B Campo
Prostate Cancer Prostatic Dis 9: 266-269; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500877
The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting
C Kastner, J Armitage, A Kimble, J Rawal, P G Carter and S Venn
Prostate Cancer Prostatic Dis 9: 270-274; advance online publication, June 13, 2006; doi:10.1038/sj.pcan.4500889
Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer
M Naoe, Y Ogawa, T Shichijo, K Fuji, T Fukagai and H Yoshida
Prostate Cancer Prostatic Dis 9: 275-278; advance online publication, June 20, 2006; doi:10.1038/sj.pcan.4500891
Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression
H Augustin, C Freibauer, L Bayer, G Lunglmayr, F Tschurlovich, W Kuber and K Pummer
Prostate Cancer Prostatic Dis 9: 279-283; advance online publication, May 16, 2006; doi:10.1038/sj.pcan.4500883
Germline BCL-2 sequence variants and inherited predisposition to prostate cancer
L R Kidd, A Coulibaly, T M Templeton, W Chen, L O Long, T Mason, C Bonilla, F Akereyeni, V Freeman, W Isaacs, C Ahaghotu and R A Kittles
Prostate Cancer Prostatic Dis 9: 284-292; advance online publication, May 30, 2006; doi:10.1038/sj.pcan.4500884
Evidence of a novel biomarker, 
s1-Casein, a milk protein, in benign prostate hyperplasia
K Xu, M-T Ling, X Wang and Y-C Wong
Prostate Cancer Prostatic Dis 9: 293-297; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500872
Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q
K A White, E M Lange, A M Ray, K J Wojno and K A Cooney
Prostate Cancer Prostatic Dis 9: 298-302; advance online publication, May 30, 2006; doi:10.1038/sj.pcan.4500878
Prostate cancer incidence varies among males from different Y-chromosome lineages
A A Ewis, J Lee, T Naroda, T Sano, S Kagawa, T Iwamoto, T Shinka, Y Shinohara, M Ishikawa, Y Baba and Y Nakahori
Prostate Cancer Prostatic Dis 9: 303-309; advance online publication, May 9, 2006; doi:10.1038/sj.pcan.4500876
Abstracts
Prostate cancer — a meeting of minds FREE
Prostate Cancer Prostatic Dis 9: 310-335; doi:10.1038/sj.pcan.4500897
